Vir Biotechnology is a biotechnology business based in the US. Vir Biotechnology stocks (VIR.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $36.39 – an increase of 7.23% over the previous week. Vir Biotechnology employs 340 staff and has a trailing 12-month revenue of around $72.6 million.
How to buy Vir Biotechnology stock in Canada
- Choose a platform. If you're a beginner, our stock trading table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: VIR in this case.
- Research Vir Biotechnology stocks. The platform should provide the latest information available.
- Buy your Vir Biotechnology stocks. It's that simple.
What's in this guide?
- Can I buy shares in Vir Biotechnology?
- Has coronavirus impacted Vir Biotechnology shares?
- Vir Biotechnology shares summary
- Compare share dealing platforms
- Is Vir Biotechnology stock a buy or sell?
- Vir Biotechnology performance over time
- Can I short Vir Biotechnology shares?
- Vir Biotechnology's financials
- Does Vir Biotechnology pay a dividend?
- Other common questions
How has Coronavirus impacted Vir Biotechnology's stock price?
Since the stock market crash in March caused by coronavirus, Vir Biotechnology's stock price has had significant positive movement.
Its last market close was $44.94, which is 63.82% up on its pre-crash value of $16.26 and 179.30% up on the lowest point reached during the March crash when the stocks fell as low as $16.09.
If you had bought $1,000 worth of Vir Biotechnology stocks at the start of February 2020, those stocks would have been worth $1,605.35 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,970.62.
Vir Biotechnology stock priceUse our graph to track the performance of VIR stocks over time.
Vir Biotechnology stocks at a glance
|Latest market close||$44.94|
|52-week range||$25.31 - $83.5|
|50-day moving average||$42.1383|
|200-day moving average||$48.9147|
|Wall St. target price||$81.17|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-5.76|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Vir Biotechnology stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Vir Biotechnology price performance over time
|1 month (2021-06-30)||-4.95%|
|3 months (2021-04-30)||-5.87%|
Vir Biotechnology financials
|Revenue TTM||USD$72.6 million|
|Gross profit TTM||USD$-196,511,000|
|Return on assets TTM||-25.36%|
|Return on equity TTM||-75.7%|
|Market capitalisation||USD$4.8 billion|
TTM: trailing 12 months
How to short and sell Vir Biotechnology stocks
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "VIR.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 8.6 million Vir Biotechnology stocks held short by investors – that's known as Vir Biotechnology's "short interest". This figure is 2.3% up from 8.4 million last month.
There are a few different ways that this level of interest in shorting Vir Biotechnology stocks can be evaluated.
Vir Biotechnology's "short interest ratio" (SIR)
Vir Biotechnology's "short interest ratio" (SIR) is the quantity of Vir Biotechnology stocks currently shorted divided by the average quantity of Vir Biotechnology stocks traded daily (recently around 799774.46610956). Vir Biotechnology's SIR currently stands at 10.77. In other words for every 100,000 Vir Biotechnology stocks traded daily on the market, roughly 10770 stocks are currently held short.
However Vir Biotechnology's short interest can also be evaluated against the total number of Vir Biotechnology stocks, or, against the total number of tradable Vir Biotechnology stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vir Biotechnology's short interest could be expressed as 0.07% of the outstanding stocks (for every 100,000 Vir Biotechnology stocks in existence, roughly 70 stocks are currently held short) or 0.1232% of the tradable stocks (for every 100,000 tradable Vir Biotechnology stocks, roughly 123 stocks are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the stock price and a discouraging interest in betting against Vir Biotechnology.
Find out more about how you can short Vir Biotechnology stock.
Vir Biotechnology stock dividends
We're not expecting Vir Biotechnology to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.
Vir Biotechnology overview
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.
Stocks similar to Vir Biotechnology
Vir Biotechnology in the news
11 Best Pharma and Biotech Stocks to Buy According to Jim Simons’ Euclidean Capital
Europe buys 220,000 doses of Vir, GSK's experimental COVID-19 treatment
European Commission To Procure 220K Doses Of Glaxo-Vir Biotech's COVID-19 Antibody
Frequently asked questions
More guides on Finder
How to buy Wheels Up (UP) stock in Canada when it goes public
Everything we know about the Wheels Up IPO, plus information on how to buy in.
How to buy Brookfield Asset Management Reinsurance Partners Ltd (BAMR) stock in Canada when it goes public
Everything we know about the Brookfield Asset Management Reinsurance Partners Ltd IPO, plus information on how to buy in.
How to buy Traeger (COOK) stock in Canada when it goes public
Everything we know about the Traeger IPO, plus information on how to buy in.
How to buy Teads (TEAD) stock in Canada when it goes public
Everything we know about the Teads IPO, plus information on how to buy in.
How to buy Snap One Holdings Corp (SNPO) stock in Canada
Everything we know about the Snap One Holdings Corp IPO, plus information on how to buy in.
How to buy Riskified (RSKD) stock in Canada
Everything we know about the Riskified IPO, plus information on how to buy in.
How to buy Preston Hollow Community Capital (PHCC) stock in Canada when it goes public
Everything we know about the Preston Hollow Community Capital IPO, plus information on how to buy in.
How to buy PowerSchool Holdings (PWSC) stock in Canada
Everything we know about the PowerSchool Holdings IPO, plus information on how to buy in.
How to buy MeridianLink (MLNK) stock in Canada
Everything we know about the MeridianLink IPO, plus information on how to buy in.
How to buy Dole (DOLE) stock in Canada when it goes public
Everything we know about the Dole IPO, plus information on how to buy in.